TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer ; volume:21 ; number:1 ; day:6 ; month:4 ; year:2021 ; pages:1-13 ; date:12.2021
BMC cancer ; 21, Heft 1 (6.4.2021), 1-13, 12.2021
- Creator
-
Cabioglu, Neslihan
Onder, Semen
Oner, Gizem
Karatay, Hüseyin
Tukenmez, Mustafa
Muslumanoglu, Mahmut
İgci, Abdullah
Eralp, Yeşim
Aydiner, Adnan
Saip, Pınar
Yavuz, Ekrem
Ozmen, Vahit
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-021-08054-6
- URN
-
urn:nbn:de:101:1-2021052819504641162751
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cabioglu, Neslihan
- Onder, Semen
- Oner, Gizem
- Karatay, Hüseyin
- Tukenmez, Mustafa
- Muslumanoglu, Mahmut
- İgci, Abdullah
- Eralp, Yeşim
- Aydiner, Adnan
- Saip, Pınar
- Yavuz, Ekrem
- Ozmen, Vahit
- SpringerLink (Online service)
Other Objects (12)
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer
Timing of additional neoadjuvant chemotherapy in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy and total mesorectal excision
CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy
Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
Tracking the dropout patients of neoadjuvant chemotherapy with locally advanced oral cavity cancer
Neoadjuvant Chemoradiation Combined with Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy alone for patients with locally advanced rectal cancer: a propensity-score-matched analysis combined with SEER validation
Tils
Tils
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer
Timing of additional neoadjuvant chemotherapy in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy and total mesorectal excision
CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy
Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
Tracking the dropout patients of neoadjuvant chemotherapy with locally advanced oral cavity cancer
Neoadjuvant Chemoradiation Combined with Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy alone for patients with locally advanced rectal cancer: a propensity-score-matched analysis combined with SEER validation
Tils
Tils
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
High platelet-to-lymphocyte ratios in triple-negative breast cancer associates with immunosuppressive status of TILs
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer
Timing of additional neoadjuvant chemotherapy in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy and total mesorectal excision
CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy
Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
Tracking the dropout patients of neoadjuvant chemotherapy with locally advanced oral cavity cancer
Neoadjuvant Chemoradiation Combined with Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer
Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy alone for patients with locally advanced rectal cancer: a propensity-score-matched analysis combined with SEER validation
Tils